Testosterone supplementation does not worsen lower urinary tract symptoms

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1828-1833

  Pearl, Jeffrey A ^b   Berhanu, Daniel ^b   François, Nathaly ^a   Masson, Puneet ^b   Zargaroff, Sherwin ^c   Cashy, John ^b   McVary, Kevin T ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c New York Urological Associates Inc   (United States)

Author keywords

Androgens; Hormone replacement therapy; Lower urinary tract symptoms; Prostatic hyperplasia; Testosterone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ANDROGEN THERAPY; ARTICLE; DISEASE COURSE; HUMAN; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; REFERENCE DATABASE; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION;

EID: 84888645327     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.111     Document Type: Article

References (29)

1. Araujo AB, O'Donnell AB, Brambilla DJ et al: Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920.
2. Harman SM, Metter EJ, Tobin JD et al: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724.
3. Surampudi PN, Wang C and Swerdloff R: Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012; 2012: 625434.
4. Travison TG, Araujo AB, O'Donnell AB et al: A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab 2007; 92: 196.
5. Douglas TH, Connelly RR, McLeod DG et al: Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59: 246.
6. Tenover JS: Androgen administration to aging men. Endocrinol Metab Clin North Am 1994; 23: 877.
7. Morales A: Androgen replacement therapy and prostate safety. Eur Urol 2002; 41: 113.
8. Bhasin S, Storer TW, Berman N et al: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407.
9. Behere HM: Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994; 40: 341.
10. Sih R, Morley JE, Kaiser FE et al: Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661.
11. Kenny AM, Kleppinger A, Annis K et al: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010; 58: 1134.
12. Sandoz Inc. Testosterone cypionate injection, USP: N.p., April 2007.
13. AndroGel- (testosterone gel) 1% for topical use. Available at www.rxlist.com/androgel-drug/consumer-side-effects-precautions.htm, page 4. Accessed April 22, 2013.
14. Behre HM, Kliesch S, Leifke E et al: Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386.
15. Marks LS, Mazer NA, Mostaghel E et al: Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351.
16. Tenover JL: Androgen deficiency in aging men. Aging Male 1998; 1: 16.
17. Raynaud JP, Gardette J, Rollet J et al: Prostatespecific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int 2013; 111: 880.
18. Feneley MR and Carruthers M: Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med 2012; 9: 2138.
19. Favilla V, Cimino S, Castelli T et al: Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int 2010; 106: 1700.
20. Moon du G, Park MG, Lee SW et al: The efficacy and safety of testosterone undecanoate (Nebido()) in testosterone deficiency syndrome in Korea: a multicenter prospective study. J Sex Med 2010; 7: 2253.
21. Coward RM, Simhan J and Carson CC 3rd: Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009; 103: 1179.
22. Nicholson TM and Ricke WA: Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011; 82: 184.
23. Barry MJ, Williford WO, Chang Y et al: Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770.
24. Rhoden EL and Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482.
25. Morales A: Androgen deficiency in the aging male. In: Campbell-Walsh Urology, 10th ed. Edited by AJ Wein, LR Kavoussi, AC Novick et al. Philadelphia: Saunders Elsevier 2011; chapt 29.
26. Helfand BT, Fought A, Manvar AM et al: Determining the utility of recalled lower urinary tract symptoms. Urology 2010; 76: 442.
27. Barry MJ, Fowler FJ Jr, O'Leary MP et al: Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol 1992; 148: 1558.
28. Barry MJ, Fowler FJ Jr, O'Leary MP et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549.
29. Quek KF, Low WY, Razack AH et al: Reliability and validity of the International Prostate Symptom Score in a Malaysian population. BJU Int 2001; 88: 21.